Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

This study has been completed.

Sponsor:

Collaborator:

Pfizer

Information provided by:

University of Pittsburgh

ClinicalTrials.gov Identifier:

NCT00259649

First received: November 26, 2005

Last updated: July 1, 2011

Last verified: June 2011

History of Changes

Purpose

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Condition	Intervention	Phase
Migraine	Drug: eletriptan	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention
Official Title:	Assessment and Prevention of Menstrual Migraine: Phase 1-prospective Survey of Self-identified Menstrual Migraine. Phase 2-prevention of Menstrual Migraine With Relpax

Resource links provided by NLM:

MedlinePlus related topics: Menstruation Migraine

Drug Information available for: Eletriptan Eletriptan Hydrobromide

U.S. FDA Resources

Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:

Change in Mean Headache Index Score Among Patients [ Time Frame: baseline to approximately three months ]
Headache index is an average headache severity score recorded using a 0-10 severity scale recorded 4 times daily. Scores are averaged to produce an average severity score which can range between 0 (no headaches) to 10 (always a maximum severity headache). Change in headache activity was evaluated by comparing mean severity scores during the 3 months pre-intervention are compared with 3 months of preventive therapy


Enrollment:	71
Study Start Date:	August 2004
Primary Completion Date:	August 2008 (Final data collection date for primary outcome measure)

Intervention Details:

oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days

Other Name: Relpax

Detailed Description:

Women are followed prospectively for 3 months, recording headaches, other symptoms, and menstrual periods. Those with menstrual migraine are treated perimenstrually with eletriptan for 3 months.

Eligibility


Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

age 18-45 healthy menstruating female

Exclusion Criteria:

cardiac or other conditions precluding use of eletriptan

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00259649

Locations


United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15206

Sponsors and Collaborators

University of Pittsburgh

Pfizer

Investigators


Principal Investigator:	Dawn Marcus, MD	University of Pittsburgh

More Information


Responsible Party:	Dawn marcus, University of Pittsburgh
ClinicalTrials.gov Identifier:	NCT00259649 History of Changes
Other Study ID Numbers:	901423
Study First Received:	November 26, 2005
Results First Received:	May 26, 2011
Last Updated:	July 1, 2011

Additional relevant MeSH terms:


Migraine Disorders Premenstrual Syndrome Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Menstruation Disturbances	Pathologic Processes Eletriptan Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs

ClinicalTrials.gov processed this record on July 18, 2017

To Top